* 中国复星医药2196.HK600196.SS旗下研发生物类似药的复宏汉霖2696.HK周二早盘一度升4.7%，早市收高1.7%。
* 该公司此前公告称，HLX07联合汉斯状（斯鲁利单抗注射液）和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药品监督管理局批准。
* 复宏汉霖今年迄今劲涨21.1%，同期恒生指数.HSI上扬1.8%。
* 恒⽣⽣物科技指数.HSBIO早市收高2.3%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 吴云凌)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.